Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Communications
16 pending office actions • 10 art units • 15 examiners • 0 of 16 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Sloan-Kettering Institute for Cancer Research has 15 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 15 distinct examiners, meaning that every pending matter is undergoing review by a different person. This distribution suggests a broad exposure to various examiner perspectives across the institute's current filings. The portfolio's activity spans 10 distinct art units, reflecting a wide technical range within the Biotechnology & Pharmaceuticals sector.
KY, KEVIN is the busiest examiner, currently managing 1 busiest examiner pending action. Because the busiest examiner pending count is 1, the 15 pending office actions are evenly split among the 15 distinct examiners. This high level of dispersion across 10 distinct art units and 15 different reviewers indicates a complex prosecution landscape where each application likely requires a tailored approach. Practitioners must navigate the specific requirements of many different technical groups, as the institute's 15 pending office actions are not concentrated under any single administrative or examiner-level bottleneck.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (12%) |
| §103 only | 6 (38%) |
| §112 only | 2 (12%) |
| Double-patenting + other | 3 (19%) |
| Multi-statute (no §101) | 3 (19%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 2 | 44.8% | +41.7% |
| KY, KEVIN | 1 | 77.4% | +25.2% |
| SHARIFF, MICHAEL ADAM | 1 | 80.8% | +24.7% |
| JASANI, ASHISH SHIRISH | 1 | 68.6% | +25.1% |
| AHMED, SAMIR ANWAR | 1 | 87.8% | +12.4% |
| ROCHELLE, CIERRA MARIE | 1 | 100.0% | +0.0% |
| HANSEN, CONNOR LEVI | 1 | 71.2% | +38.3% |
| ROBERTS, RACHEL L | 1 | 73.0% | +24.0% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18881208 | DETERMINING PREDICTED OUTCOMES OF SUBJECTS WITH CANCER BASED ON SEGMENTATIONS OF BIOMEDICAL IMAGES | SHARIFF, MICHAEL ADAM | — |
| 18856807 | MULTI-MODAL MACHINE LEARNING TO DETERMINE RISK STRATIFICATION | AHMED, SAMIR ANWAR | — |
| 18840416 | METHODS FOR TREATING CANCER PATIENTS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY BASED ON TEMPLATED INSERTIONS | ROCHELLE, CIERRA MARIE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18856763 | AUTOMATED METHODS FOR DETERMINING FIBROGLANDULAR DENSITY ON MAMMOGRAMS | JASANI, ASHISH SHIRISH | 33d |
| 18998107 | SYSTEMS AND METHODS FOR AUTOMATED TUMOR SEGMENTATION IN RADIOLOGY IMAGING USING DATA MINED LINE ANNOTATIONS | KY, KEVIN | — |
| 18838097 | AUTOMATED CHROMOGENIC IN SITU HYBRIDIZATION QUANTIFICATION AND IMMUNOHISTOCHEMICAL ASSESSMENT FROM WHOLE SLIDE IMAGES | HANSEN, CONNOR LEVI | — |
| 18708163 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | JUEDES, AMY E | — |
| 18554176 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | JOHANSEN, PETER N. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18856763 | AUTOMATED METHODS FOR DETERMINING FIBROGLANDULAR DENSITY ON MAMMOGRAMS | JASANI, ASHISH SHIRISH | 33d |
| 18998107 | SYSTEMS AND METHODS FOR AUTOMATED TUMOR SEGMENTATION IN RADIOLOGY IMAGING USING DATA MINED LINE ANNOTATIONS | KY, KEVIN | — |
| 18881208 | DETERMINING PREDICTED OUTCOMES OF SUBJECTS WITH CANCER BASED ON SEGMENTATIONS OF BIOMEDICAL IMAGES | SHARIFF, MICHAEL ADAM | — |
| 18856807 | MULTI-MODAL MACHINE LEARNING TO DETERMINE RISK STRATIFICATION | AHMED, SAMIR ANWAR | — |
| 18838097 | AUTOMATED CHROMOGENIC IN SITU HYBRIDIZATION QUANTIFICATION AND IMMUNOHISTOCHEMICAL ASSESSMENT FROM WHOLE SLIDE IMAGES | HANSEN, CONNOR LEVI | — |
| 18708163 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | JUEDES, AMY E | — |
| 18705228 | SYSTEMS AND METHODS FOR GENERATING A CORRECTED PLANAR SCINTIGRAPHY IMAGE (CPSI) | ROBERTS, RACHEL L | — |
| 18703318 | ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | DUFFY, BRADLEY | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 2671 | 1 |
| 3798 | 1 |
| 2672 | 1 |
| 2674 | 1 |
| 1623 | 1 |
| 1699 | 1 |
| 1675 | 1 |
| 1672 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18998107 | SYSTEMS AND METHODS FOR AUTOMATED TUMOR SEGMENTATION IN RADIOLOGY IMAGING USING DATA MINED LINE ANNOTATIONS | KY, KEVIN | 2671 | §102§103 | Non-Final OA | — | Pending | Jan 23, 2025 |
| 18881208 | DETERMINING PREDICTED OUTCOMES OF SUBJECTS WITH CANCER BASED ON SEGMENTATIONS OF BIOMEDICAL IMAGES | SHARIFF, MICHAEL ADAM | — | §103 | Non-Final OA | — | Pending | Jan 03, 2025 |
| 18856763 | AUTOMATED METHODS FOR DETERMINING FIBROGLANDULAR DENSITY ON MAMMOGRAMS | JASANI, ASHISH SHIRISH | 3798 | §102§103 | Final Rejection | 33d | Pending | Oct 14, 2024 |
| 18856807 | MULTI-MODAL MACHINE LEARNING TO DETERMINE RISK STRATIFICATION | AHMED, SAMIR ANWAR | — | §103 | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18840416 | METHODS FOR TREATING CANCER PATIENTS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY BASED ON TEMPLATED INSERTIONS | ROCHELLE, CIERRA MARIE | — | §103 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18838097 | AUTOMATED CHROMOGENIC IN SITU HYBRIDIZATION QUANTIFICATION AND IMMUNOHISTOCHEMICAL ASSESSMENT FROM WHOLE SLIDE IMAGES | HANSEN, CONNOR LEVI | 2672 | §102§103 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18708163 | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS INCLUDING THE SAME | JUEDES, AMY E | — | §101§102§103§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 18705228 | SYSTEMS AND METHODS FOR GENERATING A CORRECTED PLANAR SCINTIGRAPHY IMAGE (CPSI) | ROBERTS, RACHEL L | 2674 | §103 | Final Rejection | — | Pending | Apr 26, 2024 |
| 18703318 | ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | DUFFY, BRADLEY | — | §103 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18690228 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18565767 | METHODS FOR PREDICTING AND TREATING CHEMORESISTANCE IN SMALL CELL LUNG CANCER PATIENTS | BAUSCH, SARAE L | 1699 | §112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18554184 | COMBINATION THERAPY WITH DEXAMETHASONE AND TUMOR-SPECIFIC T CELL ENGAGING MULTI-SPECIFIC ANTIBODIES FOR TREATING CANCER | BENAVIDES, JENNIFER ANN | 1675 | §103§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18554176 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | JOHANSEN, PETER N. | 1644 | §101§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18550914 | METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS | JUEDES, AMY E | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18350454 | METHODS AND COMPOSITIONS FOR SENSITIZING PRC2 MUTANT TUMORS TO IMMUNE CHECKPOINT BLOCKADE THERAPY | ALAM, DANYAL HASSAN | 1672 | §103 | Final Rejection | 8d overdue | Pending | Jul 11, 2023 |
| 17427502 | DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS | LEE, HOI YAN NMN | 1693 | §103DP | Final Rejection | — | Pending | Jul 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial